| Role of OncoTherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK/RANKL signaling: New therapeutic perspective for non-muscle invasive … WJ Fávaro, SR Iantas, JM Gonçalves, QC Dias, IB Reis, A Billis, N Duran, ... Journal of Clinical Oncology 37 (15_suppl), e16004-e16004, 2019 | 19 | 2019 |
| OncoTherad: A new nanobiological response modifier, its toxicological and anticancer activities N Durán, QC Dias, WJ Fávaro Journal of Physics: Conference Series 1323 (1), 012018, 2019 | 13 | 2019 |
| Purification and inflammatory edema induced by two PLA2 (Anch TX-I and Anch TX-II) from sea anemone Anthothoe chilensis (Actiniaria: Sagartiidae) ECT Landucci, QC Dias, FA Marangoni, A Vilca-Quispe, ... Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular …, 2012 | 12 | 2012 |
| Potential therapeutic strategies for non-muscle invasive bladder cancer based on association of intravesical immunotherapy with P-MAPA and systemic administration of cisplatin … QC Dias, IS Nunes, PV Garcia, WJ Fávaro International braz j urol 42, 942-954, 2016 | 11 | 2016 |
| New synthetic nano-immunotherapy (OncoTherad®) for non-muscle invasive bladder cancer: Its synthesis, characterization and anticancer property WJ Fávaro, JCC Alonso, BR De Souza, IB Reis, JM Gonçalves, ... Tissue and Cell 80, 101988, 2023 | 5 | 2023 |
| Associating Graphene Oxide Derivatives to Treat Non-Muscle Invasive Bladder Cancer (NMIBC) WJ Fávaro, JG de Souza, MY Matsumoto, M Durán, PK Bockelmann, ... Biointerface Res. Appl. Chem 12, 196-210, 2021 | 3 | 2021 |
| A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad® immunotherapy associated with platelet-rich plasma BR de Souza, IB Reis, GC de Arruda Camargo, G Oliveira, QC Dias, ... International immunopharmacology 123, 110723, 2023 | 2 | 2023 |
| Clinical Implications of Immune Checkpoints and the RANK/RANK-L Signaling Pathway in High-Grade Canine Mast Cell Tumors NC Talavera Guillén, A Barboza de Nardi, F Noleto de Paiva, QC Dias, ... Animals 13 (12), 1888, 2023 | 1 | 2023 |
| A potential new therapeutic option for the treatment of nonmuscle invasive bladder cancer: Combination of intravesical oncotherad immunotherapy and platelet rich plasma (PRP). BRS Sasaki, GCA Camargo, IB Reis, QC Dias, N Duran, WJ Fávaro Journal of Clinical Oncology 39 (6_suppl), 461-461, 2021 | 1 | 2021 |
| Caracterização dos efeitos da imunoterapia com OncoTherad no câncer de bexiga não-músculo invasivo: análise da regressão tumoral e sobrevida pós-tratamento M da Silva, W Favaro, Q Dias, N Durán Revista dos Trabalhos de Iniciação Científica da UNICAMP, 1-1, 2019 | 1 | 2019 |
| Nanoparticles by Fungi and Cancer Applications N Durán, MB de Jesus, QC Dias, G Nakazato, WJ Fávaro Myconanotechnology: Emerging Trends and Applications, 29, 2023 | | 2023 |
| Synthesis of Biogenic Nanoparticles by Fungi and Cancer Applications 2 N Durán, MB de Jesus, QC Dias, G Nakazato, WJ Fávaro Myconanotechnology, 29-52, 2023 | | 2023 |
| Nanocrystal's Formulation of Biological Response Modifier P-MAPA on Bladder Cancer Compared to Bacillus Calmette-Guerin Immunomodulator JF Wagner, ACS Lima, QC Dias, PV Garcia, N Durán Turkish Journal of Oncology 37 (2), 2022 | | 2022 |
| Características dos tratamentos e seus efeitos na sobrevida de ratos induzidos quimicamente ao câncer de bexiga não-músculo invasivo (CBNMI): novas perspectivas terapêuticas … QC Dias [sn], 2020 | | 2020 |
| New therapeutic approaches for non-muscle invasive bladder cancer (NMIBC): intravesical use of oncotherad biological response modifier and its association with platelet-rich … G Camargo, W Favaro, B Sasaki, I Reis, Q Dias, N Durán Revista dos Trabalhos de Iniciação Científica da UNICAMP, 1-1, 2019 | | 2019 |
| Nova perspectiva terapêutica para o câncer de bexiga não-músculo invasivo baseada na imunoterapia intravesical com OncoTherad: análises toxicológicas e de efetividade antitumoral MS da Silva, WJ Favaro, QC Dias, N Durán Revista dos Trabalhos de Iniciação Científica da UNICAMP, 2018 | | 2018 |
| Potenciais Estratégias Terapêuticas para o Câncer de Bexiga urinária não-músculo invasivo baseadas na associação da Imunoterapia intravesical com P-MAPA e administrações … QC Dias [sn], 2015 | | 2015 |
| QUEILA CRISTINA DIAS VFDATD PELA, AQCDE ORIENTADA, PPDRWJ FAVARO | | |
